12/25
08:00 am
avxl
We're Not Worried About Anavex Life Sciences' (NASDAQ:AVXL) Cash Burn [Yahoo! Finance]
Low
Report
We're Not Worried About Anavex Life Sciences' (NASDAQ:AVXL) Cash Burn [Yahoo! Finance]
12/23
08:57 am
avxl
Anavex Life Sciences Corp. (NASDAQ: AVXL) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $46.00 price target on the stock.
High
Report
Anavex Life Sciences Corp. (NASDAQ: AVXL) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $46.00 price target on the stock.
12/23
07:37 am
avxl
Anavex Life Sciences Reports Fiscal 2024 Fourth Quarter Financial Results and Provides Business Update [Yahoo! Finance]
High
Report
Anavex Life Sciences Reports Fiscal 2024 Fourth Quarter Financial Results and Provides Business Update [Yahoo! Finance]
12/23
07:30 am
avxl
Anavex Life Sciences Reports Fiscal 2024 Fourth Quarter Financial Results and Provides Business Update
High
Report
Anavex Life Sciences Reports Fiscal 2024 Fourth Quarter Financial Results and Provides Business Update
12/23
07:17 am
avxl
Blarcamesine Receives EMA Filing Acceptance for Treatment of Alzheimer's Disease [Yahoo! Finance]
High
Report
Blarcamesine Receives EMA Filing Acceptance for Treatment of Alzheimer's Disease [Yahoo! Finance]
12/23
07:00 am
avxl
Blarcamesine Receives EMA Filing Acceptance for Treatment of Alzheimer’s Disease
High
Report
Blarcamesine Receives EMA Filing Acceptance for Treatment of Alzheimer’s Disease
12/22
05:03 am
avxl
What To Expect in the Markets This Week [Yahoo! Finance]
High
Report
What To Expect in the Markets This Week [Yahoo! Finance]
12/16
07:47 am
avxl
Anavex Life Sciences to Announce Fiscal 2024 Fourth Quarter Financial Results on Monday, December 23, 2024 [Yahoo! Finance]
Medium
Report
Anavex Life Sciences to Announce Fiscal 2024 Fourth Quarter Financial Results on Monday, December 23, 2024 [Yahoo! Finance]
12/16
07:30 am
avxl
Anavex Life Sciences to Announce Fiscal 2024 Fourth Quarter Financial Results on Monday, December 23, 2024
Medium
Report
Anavex Life Sciences to Announce Fiscal 2024 Fourth Quarter Financial Results on Monday, December 23, 2024
12/9
07:30 am
avxl
Anavex Life Sciences to Report New Long-Term Oral Blarcamesine Phase IIb/III Alzheimer’s Disease Data at J.P. Morgan 2025 Healthcare Conference
Low
Report
Anavex Life Sciences to Report New Long-Term Oral Blarcamesine Phase IIb/III Alzheimer’s Disease Data at J.P. Morgan 2025 Healthcare Conference
12/2
07:30 am
avxl
Anavex Life Sciences to Present at the 7th Annual Evercore ISI HealthCONx Conference 2024
Medium
Report
Anavex Life Sciences to Present at the 7th Annual Evercore ISI HealthCONx Conference 2024
11/27
08:05 am
avxl
Anavex Life Sciences Corp. (NASDAQ: AVXL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $40.00 price target on the stock.
Low
Report
Anavex Life Sciences Corp. (NASDAQ: AVXL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $40.00 price target on the stock.
11/26
07:43 am
avxl
Anavex Life Sciences Announces Submission of Blarcamesine MAA for Treatment of Alzheimer's Disease to EMA [Yahoo! Finance]
Medium
Report
Anavex Life Sciences Announces Submission of Blarcamesine MAA for Treatment of Alzheimer's Disease to EMA [Yahoo! Finance]
11/26
07:30 am
avxl
Anavex Life Sciences Announces Submission of Blarcamesine MAA for Treatment of Alzheimer’s Disease to EMA
Low
Report
Anavex Life Sciences Announces Submission of Blarcamesine MAA for Treatment of Alzheimer’s Disease to EMA
11/25
09:08 am
avxl
Anavex Life Sciences Corp. (NASDAQ: AVXL) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $46.00 price target on the stock.
Medium
Report
Anavex Life Sciences Corp. (NASDAQ: AVXL) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $46.00 price target on the stock.
11/25
07:40 am
avxl
Anavex Life Sciences Announces Acceptance of Peer-Reviewed Manuscript of Oral Blarcamesine Phase IIb/III Data in a Reference Alzheimer's Disease Journal [Yahoo! Finance]
Low
Report
Anavex Life Sciences Announces Acceptance of Peer-Reviewed Manuscript of Oral Blarcamesine Phase IIb/III Data in a Reference Alzheimer's Disease Journal [Yahoo! Finance]
11/25
07:30 am
avxl
Anavex Life Sciences Announces Acceptance of Peer-Reviewed Manuscript of Oral Blarcamesine Phase IIb/III Data in a Reference Alzheimer’s Disease Journal
Low
Report
Anavex Life Sciences Announces Acceptance of Peer-Reviewed Manuscript of Oral Blarcamesine Phase IIb/III Data in a Reference Alzheimer’s Disease Journal
11/6
05:13 am
avxl
Anavex Life Sciences: Weighing The Pros And Cons Of A Possible EU Approval Scenario [Seeking Alpha]
Low
Report
Anavex Life Sciences: Weighing The Pros And Cons Of A Possible EU Approval Scenario [Seeking Alpha]
11/4
08:19 am
avxl
Anavex Life Sciences Corp. (NASDAQ: AVXL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $40.00 price target on the stock.
Medium
Report
Anavex Life Sciences Corp. (NASDAQ: AVXL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $40.00 price target on the stock.
10/31
04:07 am
avxl
Anavex's Blarcamesine Achieves Pre-specified Efficacy in Phase IIb/III Alzheimer's Trial: Data Presented at CTAD Conference 2024 [Yahoo! Finance]
High
Report
Anavex's Blarcamesine Achieves Pre-specified Efficacy in Phase IIb/III Alzheimer's Trial: Data Presented at CTAD Conference 2024 [Yahoo! Finance]
10/31
04:00 am
avxl
Anavex’s Blarcamesine Achieves Pre-specified Efficacy in Phase IIb/III Alzheimer’s Trial: Data Presented at CTAD Conference 2024
High
Report
Anavex’s Blarcamesine Achieves Pre-specified Efficacy in Phase IIb/III Alzheimer’s Trial: Data Presented at CTAD Conference 2024
10/18
08:33 am
avxl
Anavex Life Sciences Corp. (NASDAQ: AVXL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $40.00 price target on the stock.
Low
Report
Anavex Life Sciences Corp. (NASDAQ: AVXL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $40.00 price target on the stock.
10/17
07:30 am
avxl
Anavex Life Sciences Announces Encouraging Preliminary Biomarker Results from Ongoing Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia
Low
Report
Anavex Life Sciences Announces Encouraging Preliminary Biomarker Results from Ongoing Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia